A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors

A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors
Conditions: Solid Tumor, Adult; NSCLC; Urothelial Carcinoma; Gastric Cancer; Small Cell Lung Cancer; Hepatocellular Carcinoma; Cervical Carcinoma; Melanoma; Renal Cell Carcinoma; Carcinoma

Interventions: Biological: BA3071; Biological: Nivolumab; Biological: Pembrolizumab

Sponsors: BioAtla, Inc.

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 15, 2023Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments